Spots Global Cancer Trial Database for CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
Official Title: Phase I, Interventional, Single Arm, Open Label, Treatment Study to Evaluate the Safety and Tolerability of CD19 CARvac in Patients With Relapsed and/or Refractory B Cell Malignancies
Study ID: NCT04156243
Interventions
Study Description
Brief Summary: This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.
Detailed Description: CD19 CARvac is a chimeric antigen receptor immunotherapy treatment designed to treat
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The General Hospital of Western Theater Command, Chengdu, , China
Peking University Shenzhen Hospital, Shenzhen, , China
Contact Details
Name: Hongyu Zhang, MD, PhD
Affiliation: Peking University Shenzhen Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Fang Liu, MD, PhD
Affiliation: The General Hospital of Western Theater Command
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
